herceptin&breast cancer treatment

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2018/04/20 06:57:02」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results.
  • Aapro M, Finek J.SourceMultidisciplinary Institute of Oncology, CH 1272, Genolier, Switzerland.
  • Cancer treatment reviews.Cancer Treat Rev.2012 Apr;38(2):120-6. Epub 2011 Jul 13.
  • BACKGROUND: Oral chemotherapy is one of the options for the treatment of endocrine non-responsive metastatic breast cancer.PATIENTS AND METHODS: A search of the online PubMed database was undertaken to identify clinical trials evaluating oral vinorelbine in metastatic breast cancer. All the clinical
  • PMID 21742438
  • HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer.
  • Tsé C, Gauchez AS, Jacot W, Lamy PJ.SourceLaboratoire de Biochimie Métabolique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Cancer treatment reviews.Cancer Treat Rev.2012 Apr;38(2):133-42. Epub 2011 May 5.
  • The transmembrane protein HER2 is over-expressed in approximately 15% of invasive breast cancers as a result of HER2 gene amplification. HER2 proteolytic cleavage (HER2 shedding) generates soluble truncated HER2 molecules that include only the extracellular domain and the concentration of which can
  • PMID 21549508

Japanese Journal

  • Communication to the Editor : New Cancer Immunotherapy Using Autologous Lymphocytes Activated with Trastuzumab
  • Nakagawa Shinichirou,Matsuoka Yusuke,Ichihara Hideaki [他]
  • Biological & pharmaceutical bulletin 35(8), 1213-1215, 2012-08
  • NAID 40019353477
  • A Comparative Clinical Evaluation of the Assay of Serum Extracellular Domain of HER2 Protein Using a Chemiluminescent Immunoassay Method in Breast Cancer Patients with or without HER2 Protein Expression in Immunohistochemistry
  • MOKUYASU Seiichi,SUZUKI Yasuhiro,SETO Takayuki [他]
  • 臨床病理 : 日本臨床検査医学会誌 60(7), 612-620, 2012-07
  • NAID 40019404792

Related Links

トラスツズマブ(英: Trastuzumab)はヒト癌遺伝子HER2/neu(c-erbB-2)の遺伝子産物 であるHER2蛋白に特異的に結合する事で抗腫瘍効果を発揮する抗がん剤。癌の増殖 などに関係する特定の分子を狙い撃ちする分子標的治療薬の一種である。
Herceptin® (trastuzumab) is a HER2+ breast cancer therapy designed to treat aggressive HER positive metastatic and adjuvant breast cancer. BREAST CANCER INDICATIONS: Adjuvant indications Who is Herceptin for? Herceptin is ...








  • HER2/neu遺伝子はヒト上皮細胞増殖因子受容体遺伝子と類似の構造を有する癌遺伝子



ハーセプチン Herceptinトラツズマブ